Research & Literature

A case of fibrillary glomerulonephritis associated with thrombotic microangiopathy and anti-glomerular basement membrane antibody.

Momose A, Nakajima T, Chiba S, et al.

Nephron extra 2015; (5(1)):30-8 doi:10.1159/000371802.

Fibrillary glomerulonephritis masquerading as rapidly progressive glomerulonephritis with pseudo-linear glomerular basement membrane staining.

El-Husseini A, Aycinena JC, George B, et al.

Clinical nephrology 2015; (84(4)):231-5 doi:10.5414/CN108508.

Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician.

Vassalotti JA, Centor R, Turner BJ, et al.

The American journal of medicine 2016; (129(2)):153-162.e7.

End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.

Mallett A, Tang W, Hart G, et al.

American journal of nephrology 2015; (42(3)):177-84 doi:10.1159/000440815.

A case of mistaken identity: fibrillary glomerulonephritis masquerading as crescentic anti-glomerular basement membrane disease.

Thomas JA, Vasin D, Lin M, et al.

Clinical nephrology 2016; (85(2)):114-20 doi:10.5414/CN108667.

[Glomerulopathies with organized monoclonal immunoglobulin deposits].

Touchard G, Bridoux F, Goujon JM

Nephrologie & therapeutique 2016; (12(1)):57-65.

Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality.

Carrero JJ, Grams ME, Sang Y, et al.

Kidney international 2017; (91(1)):244-251 doi:10.1016/j.kint.2016.09.037.

Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis.

Payan Schober F, Jobson MA, Poulton CJ, et al.

American journal of nephrology 2017; (45(3)):248-256 doi:10.1159/000455390.

Histologic regression of fibrillary glomerulonephritis: the first report of biopsy-proven spontaneous resolution of disease.

Sekulic M, Nasr SH, Grande JP, Cornell LD

Clinical kidney journal 2017; (10(6)):738-741 doi:10.1093/ckj/sfx045.

DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis.

Nasr SH, Vrana JA, Dasari S, et al.

Kidney international reports 2018; (3(1)):56-64 doi:10.1016/j.ekir.2017.07.017.

Congophilic Fibrillary Glomerulonephritis: A Case Series.

Alexander MP, Dasari S, Vrana JA, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (72(3)):325-336 doi:10.1053/j.ajkd.2018.03.017.

Fibrillary Glomerulonephritis with Crescentic and Necrotizing Glomerulonephritis and Concurrent Thrombotic Microangiopathy.

Tsui C, Dokouhaki P, Prasad B

Case reports in nephrology and dialysis 2018; (8(2)):182-191 doi:10.1159/000492529.

Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring.

Leibler C, Moktefi A, Matignon M, et al.

Journal of clinical medicine 2018; (7(11)) doi:10.3390/jcm7110430.

New developments in the diagnosis of fibrillary glomerulonephritis.

Nasr SH, Fogo AB

Kidney international 2019; (96(3)):581-592 doi:10.1016/j.kint.2019.03.021.

Fibrillary Glomerulonephritis: Clinicopathologic Features and Atypical Cases from a Multi-Institutional Cohort.

Andeen NK, Troxell ML, Riazy M, et al.

Clinical journal of the American Society of Nephrology : CJASN 2019; (14(12)):1741-1750 doi:10.2215/CJN.03870319.

Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series.

El Ters M, Bobart SA, Cornell LD, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2020; (76(4)):500-510 doi:10.1053/j.ajkd.2020.01.018.

Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study.

Erickson SB, Zand L, Nasr SH, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2021; (36(1)):104-110 doi:10.1093/ndt/gfaa065.

DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients.

Said SM, Leung N, Alexander MP, et al.

Kidney international 2020; (98(2)):498-504 doi:10.1016/j.kint.2020.02.025.

Fibrillary glomerulonephritis presenting as crescentic glomerulonephritis in a young female: a case study.

Singh PP, Krishna A, Sharma A, Kumar O

Ultrastructural pathology 2020; (44(4-6)):501-504 doi:10.1080/01913123.2020.1792598.

Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy.

Javaugue V, Dufour-Nourigat L, Desport E, et al.

Kidney international 2021; (99(2)):421-430 doi:10.1016/j.kint.2020.06.039.

Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants.

Nasr SH, Kudose SS, Said SM, et al.

Kidney international 2021; (99(2)):410-420 doi:10.1016/j.kint.2020.07.037.

DNA J homolog subfamily B member 9 and other advances in fibrillary glomerulonephritis.

Andeen NK, Avasare RS

Current opinion in nephrology and hypertension 2021; (30(3)):294-302 doi:10.1097/MNH.0000000000000706.

Diagnostic Approach to Glomerulonephritis With Fibrillar IgG Deposits and Light Chain Restriction.

Kudose S, Canetta P, Andeen NK, et al.

Kidney international reports 2021; (6(4)):936-945 doi:10.1016/j.ekir.2021.01.001.

Clinicopathologic features and treatment outcomes of patients with fibrillary glomerulonephritis: A case series.

Marinaki S, Tsiakas S, Liapis G, et al.

Medicine 2021; (100(20)):e26022 doi:10.1097/MD.0000000000026022.

Donor-Derived ALECT2 Amyloidosis and Recurrent Fibrillary Glomerulonephritis in a Transplant Allograft.

Nasr SH, Chavez O, Dasari S, et al.

Kidney medicine 2021; (3(3)):433-437 doi:10.1016/j.xkme.2020.11.019.

Monoclonal gammopathy of renal significance: Spectrum of diseases and approach to a case.

Tewari R, Chatterjee T, Mendonca S, et al.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2021; (32(2)):298-306 doi:10.4103/1319-2442.335440.

Fibrillary and immunotactoid glomerulopathies in the Hunter region: a retrospective cohort study.

Cohen AWS, Vilayur E

Internal medicine journal 2023; (53(10)):1837-1845 doi:10.1111/imj.15959.

[Latest updates on immunotactoid glomerulopathy and fibrillary glomerulonephritis].

Lafargue MC, Cohen C

Bulletin du cancer 2024; (111(7-8)):741-747 doi:10.1016/j.bulcan.2022.12.014.

Fibrillary Glomerulonephritis, DNAJB9, and the Unfolded Protein Response.

Andeen NK, Kung VL, Robertson J, et al.

Glomerular diseases 2022; (2(4)):164-175 doi:10.1159/000525542.

Glomerulopathies with Fibrillary Deposits.

Dzekova-Vidimliski P, Karanfilovski V, Nikolov IG, et al.

Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) 2023; (44(2)):99-106 doi:10.2478/prilozi-2023-0030.

DNAJB9 Fibrillary Glomerulonephritis With Membranous-Like Pattern: A Case-Based Literature Review.

Sabanis N, Liaveri P, Geladari V, et al.

Cureus 2023; (15(10)):e47862 doi:10.7759/cureus.47862.

[Fibrillary glomerulonephritis].

Dumas De La Roque C, Brocheriou I, Mirouse A, et al.

La Revue de medecine interne 2024; (45(11)):703-709 doi:10.1016/j.revmed.2024.05.005.

Finerenone: Who should prescribe it for CKD? The physician associate's perspective.

Ness BM, Webb H

Journal of nephrology 2024; (37(8)):2161-2170 doi:10.1007/s40620-024-02015-5.

Immunotactoid Glomerulopathy.

Abramson M, Shaikh A

Advances in kidney disease and health 2024; (31(4)):326-333 doi:10.1053/j.akdh.2024.03.003.

Updates on the Diagnosis and Management of Fibrillary Glomerulonephritis.

Attieh RM, Yang Y, Rosenstock JL

Advances in kidney disease and health 2024; (31(4)):374-383 doi:10.1053/j.akdh.2024.03.006.

Successful Treatment of Monoclonal Immunotactoid Glomerulopathy Associated with Chronic Lymphocytic Leukemia Using Ibrutinib.

Saito A, Kameoka Y, Ubukawa K, et al.

Internal medicine (Tokyo, Japan) 2025; (64(9)):1388-1392 doi:10.2169/internalmedicine.3902-24.

Fibrillary Glomerulonephritis: Clinicopathological Characteristics and Outcome-Case Series From a Multicentre Australasian Cohort.

Komala MG, Bayly A, Lee AYS, et al.

Nephrology (Carlton, Vic.) 2025; (30(4)):e70022 doi:10.1111/nep.70022.

Dual Occurrence of DNAJB-9 Positive Fibrillary Glomerulonephritis and Diffuse Lupus Nephritis: A Unique Overlap Glomerulopathy.

Zuckerman JE, Yang T

Kidney medicine 2025; (7(6)):101008 doi:10.1016/j.xkme.2025.101008.

Fibrillary glomerulonephritis: lessons from anti-CD20 therapy and repeat biopsy.

Fenoglio R, Sciascia S, De Simone E, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025; (40(12)):2319-2325 doi:10.1093/ndt/gfaf109.

Fibrillary glomerulonephritis disease natural history and outcomes: a retrospective two centre cohort study.

Zhang Y, Baharani J, Ajayi B, Pinney J

BMC nephrology 2025; (26(1)):330 doi:10.1186/s12882-025-04187-z.

Fibrillary glomerulonephritis: an observational study of clinical-pathological features and outcomes in patients from a multi-institutional cohort.

Patrick J, Charles-Rudwick M, Quinn C, et al.

Clinical kidney journal 2025; (18(6)):sfaf166 doi:10.1093/ckj/sfaf166.

Idiopathic Fibrillary Glomerulonephritis: A Case Report Highlighting Diagnostic and Management Challenges.

Gayibov E, Gupta I

Cureus 2025; (17(7)):e87135 doi:10.7759/cureus.87135.

Cardiomyopathy in the Shadow of Fibrillary Glomerulonephritis: An Unusual Indirect Association.

Rijal S, Shah MP, Mudupula Vemula SS, et al.

Cureus 2025; (17(7)):e87879 doi:10.7759/cureus.87879.

Fibrillary glomerulonephritis: A retrospective analysis of a case series from a tertiary center.

Dovč A, Večerić-Haler Ž, Kojc N, et al.

Clinical nephrology 2025; (104 (Suppl. 1)()):S66-S72 doi:10.5414/CNP104S10.

Fibrillary glomerulonephritis: clinicopathological characteristics and treatment in a spanish tertiary center.

Tatis E, Ramos Terrades N, Gabaldón MA, et al.

Nefrologia 2026; (46(2)):501417 doi:10.1016/j.nefroe.2026.501417.

Pathological diagnosis and differential considerations of renal diseases with organized deposits under an electron microscope: key points in diagnosis.

Mii A, Yamamoto Y, Ishikawa A, Shimizu A

Clinical and experimental nephrology 2026; (30(8)):1158-1168 doi:10.1007/s10157-026-02892-z.

Clinicopathologic features and outcomes of patients with DNAJB9-positive fibrillary glomerulonephritis.

Hurdogan O, Mirioglu S, Cebeci E, et al.

Clinical kidney journal 2026; (19(5)):sfag138 doi:10.1093/ckj/sfag138.

DNAJB9 in Fibrillary Glomerulonephritis: Diagnostic Biomarker, Putative Autoantigen, or Disease-Associated Scaffold? A Case-Based Narrative Review.

Lebedev L, Mansur M, Seh M, et al.

Life (Basel, Switzerland) 2026; (16(7)) doi:10.3390/life16071186.